BRAF inhibitors and MEK inhibitors were a breakthrough in the treatment of melanoma and around 15–20% of tumors finally show primary resistance to this treatment, and moreover, some patients even develop acquired resistance to therapy. Here, MAP2K7 is linked to melanoma.